First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID

Contact: Anne A. Oplinger
NIH/National Institute of Allergy and Infectious Diseases

Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
TAG: First tuberculosis vaccine trial years begins

(Date:8/22/2014)... August 22, 2014 Braverman Eye Center ... Fort Lauderdale at the most affordable fee. They are ... through their advanced Lasik treatments. LASIK is a highly ... Braverman Eye Center has been delivering successful LASIK solutions ... a glasses-free and contact lenses-free life with the help ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ... Collaboration, Data Security & Compliance, Campus Technology, Student ... and Analysis (2014-2019)", defines and segments the global ... in-depth analysis and forecasting of market sizes. The ... various restraints and opportunities impacting it along with ...
(Date:8/22/2014)... fainting. Each year approx. 265,000 Danes are acutely admitted ... research from Aarhus University and Aarhus University Hospital now ... every fourth patient are sent home again without ... to the acute hospitalisation., "Naturally, there is no need ... disprove that there is a serious illness. So some ...
(Date:8/22/2014)... 2014 A new study finds a wide range ... be related to key environmental exposuresin children with Crohn,s disease ... journal of the Crohn,s & Colitis Foundation of America ... Williams & Wilkins , a part of Wolters Kluwer ... of alterations of DNA in several regions of the genome ...
(Date:8/22/2014)... Sweden provides insight on how the brain processes external ... sources and sides of the body, in order to ... presented in the journal Neuron , show that ... types of sensory information, with specialised functional roles for ... main input structure in the basal ganglia, and is ...
Breaking Medicine News(10 mins):Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:The striatum acts as hub for multisensory integration 2
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)... --  - MediaLINC unlocks the ... announced general availability of MediaLINC - its ... of education, entertainment and clinical content direct to standard ... " Lincor has already been ... to bedside smart devices, " comments Dan Byrne ...
(Date:8/22/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, is pleased to announce its ... conference taking place at the Faculty of Medicine ... October 22, 2014.  The multilingual conference brings together ... health professionals, and patients, to discuss the development ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
Cached News: